Authors: BOBERG M ANGERBAUER R KANHAI WK KARL W KERN A RADTKE M STEINKE W

Citation: M. Boberg et al., BIOTRANSFORMATION OF CERIVASTATIN IN MICE, RATS, AND DOGS IN-VIVO, Drug metabolism and disposition, 26(7), 1998, pp. 640-652

Authors: BOBERG M ANGERBAUER R FEY P KANHAI WK KARL W KERN A PLOSCHKE J RADTKE M

Citation: M. Boberg et al., METABOLISM OF CERIVASTATIN BY HUMAN LIVER-MICROSOMES IN-VITRO - CHARACTERIZATION OF PRIMARY METABOLIC PATHWAYS AND OF CYTOCHROME-P450 ISOZYMES INVOLVED, Drug metabolism and disposition, 25(3), 1997, pp. 321-331

Authors: BISCHOFF H ANGERBAUER R BENDER J BISCHOFF E FAGGIOTTO A PETZINNA D PFITZNER J PORTER MC SCHMIDT D THOMAS G

Citation: H. Bischoff et al., CERIVASTATIN - PHARMACOLOGY OF A NOVEL SYNTHETIC AND HIGHLY-ACTIVE HMG-COA REDUCTASE INHIBITOR, Atherosclerosis, 135(1), 1997, pp. 119-130

Authors: BISCHOFF H ANGERBAUER R BOBERG M SCHMIDT D

Citation: H. Bischoff et al., CERIVASTATIN - HIGH ENZYME AFFINITY AND ACTIVE METABOLITES CONTRIBUTETO ITS HIGH PHARMACOLOGICAL, Atherosclerosis, 130, 1997, pp. 93-93